Reviewer's report

Title: Microorganisms involved in Deep Neck Infection (DNIs) in Greece: detection, identification and susceptibility to antimicrobials

Version: 1 Date: 29 Aug 2019

Reviewer: Jiun-Ling Wang

Reviewer's report:

For the treatment recommendation esp. in the conclusion, you said "we suggest intravenous infusion of "amoxicillin-clavulanic acid combined with metronidazole"as the first-line treatment.", suggestion revision. Because other B-lactam/BL inhibitor: e.g ampicillin/sulbactam or pip/tazo may also be considered. And some experts recommended 3rd generation cephem + metronidazole. And if you consider the result "Finally, all anaerobic bacteria isolates were susceptible to clindamycin and to metronidazole." Why not use clindamycin? And what is the rationale that we can not use only B-lactam/Bactam inhibitor as empirical therapy? What is the disadvantage if you did not use metronidazole? No data or guidelines support the use of two anti-anaerobic drugs in clinical setting.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

Quality of written English
Please indicate the quality of language in the manuscript:
Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal